With withering pipelines and patent expiries  coupled with sluggish single digit growth in regulated markets Big Pharma are increasingly shifting their focus to emerging markets like India. Without doubt the opportunities in India are huge but there are several challenges for success in a rapidly changing regulatory landscape. While M&A was the essence to expand footprint till a few years back, Big Pharma are now taking the Strategic Alliance route moulded around licensing. Though no robust model has emerged the strategy seems to be founded on sharing both gains and risks. Read More...